Navigation Links
McNEIL-PPC, Inc. Acquires Full Ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Joint Venture
Date:9/28/2011

FORT WASHINGTON, Pa., Sept. 28, 2011 /PRNewswire/ -- McNEIL-PPC, Inc. and its affiliate McNeil MMP, LLC (McNEIL) announced today that they have completed the acquisition of full ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. joint venture in the United States from Merck Sharp & Dohme Corp. (Merck). The joint venture will be renamed McNeil Consumer Pharmaceuticals Co. and will continue to market products under the PEPCID®, MYLANTA®, and MYLICON® brands.

In addition, Johnson & Johnson Inc. through its McNeil Consumer Healthcare Division (McNeil Canada) has today acquired from Merck Canada Inc. its partnership interest in the Canadian joint venture.  McNeil Canada will continue to market and sell PEPCID®, 222® and FLEET ENEMA® in Canada.

Ownership of the manufacturing facility located in Lancaster, Pa., will also transfer to McNEIL-PPC, Inc.   These acquisitions will allow McNeil and McNeil Canada to enhance their positions in the United States and Canada, respectively, in the important digestive health category.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of McNEIL-PPC, Inc., Johnson & Johnson Inc. and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  McNEIL-PPC, Inc., Johnson & Johnson Inc. and Johnson & Johnson do not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE McNEIL-PPC, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. McNEIL-PPC, Inc. Announces Signing of Consent Decree Covering Manufacturing Facilities in Las Piedras, PR, Fort Washington, PA, and Lancaster, PA
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. U.S. Preventive Medicine Acquires Specialty Disease Management
5. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
6. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
7. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
8. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
9. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
10. Wound Management Technologies Acquires Resorbable Orthopedics
11. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified ... year ended 31 December 2016 compared with the previous corresponding period. ... viewed here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: ... 2015: $15.7m; up 11%) Profit before tax of ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis ... the global Oesophageal Cancer market. The research answers the ... drugs marketed for Oesophageal Cancer and their clinical attributes? How are ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Healthcare Associates of McKinney announced today that ... at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in ... , As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... Charlevoix, MI (PRWEB) , ... February 24, 2017 ... ... venue in Charlevoix, once again hosted their Military Wedding Giveaway, with the ... be hosted by Castle Farms with services generously donated from local vendors: A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare ... audience, will be participating in Rare Disease Day events, hosted by the Rare ... Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an approved content provider for the National Institute for Health and Care ... social care-related organizations in the National Health Service (NHS) to search, order and ...
Breaking Medicine News(10 mins):